{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:34:45Z","timestamp":1744425285454},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Invasive fungal infections (IFIs) contribute significantly to nosocomial illness in intensive care units (ICUs). Current practice guidelines recommend echinocandins, such as micafungin, for the treatment of invasive candidiasis. However, limited information on their use in real\u2010world practice is available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the conditions of the use of micafungin in daily clinical practice and to evaluate its effectiveness and tolerability under real\u2010world conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients\/Methods<\/jats:title><jats:p>This observational, prospective, multicentre study was performed in 34 ICUs in France. The study population consisted of 275 patients \u226516\u00a0years old who received treatment with micafungin during the inclusion period. Dose and duration of treatment were at the discretion of the physician.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Proven invasive candidiasis was documented before treatment in 106 patients (38.6%); 263 patients (95.6%) received the recommended dose (100\u00a0mg\/day); 78 patients (28.8%) were treated for the recommended duration. A successful outcome was observed for 217 patients (79.2%). This proportion was significantly higher (83.3%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.0001) in patients treated for \u226514\u00a0days. Three patients discontinued treatment due to an adverse event considered related to micafungin. No clear impact of micafungin on hepatic function was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Micafungin was effective in &gt;75% of patients treated for IFIs in ICUs in France; outcomes may be improved with closer adherence to the recommended treatment duration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/myc.13060","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T02:15:28Z","timestamp":1581473728000},"page":"443-451","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of invasive fungal infections in intensive care units with micafungin: The MYRIADE study"],"prefix":"10.1111","volume":"63","author":[{"given":"Jean\u2010Fran\u00e7ois","family":"Timsit","sequence":"first","affiliation":[{"name":"Assistance Publique des H\u00f4pitaux de Paris Medical and Infectious Diseases Intensive Care Unit Bichat Hospital Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Leverger","sequence":"additional","affiliation":[{"name":"Assistance Publique des H\u00f4pitaux de Paris Pediatric Hematology Oncology Unit Armand Trousseau Hospital Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00ebl","family":"Milpied","sequence":"additional","affiliation":[{"name":"Hematology Department Haut\u2010Leveque Hospital Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Gachot","sequence":"additional","affiliation":[{"name":"Department of Acute Care Gustave\u2010Roussy Institute \u2013 Cancer Campus Grand Paris Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318206c1ca"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3109\/1040841X.2014.974500","article-title":"Novel strategies to fight Candida species infection","volume":"42","author":"Rodrigues ME","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/591033"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01811-10"},{"key":"e_1_2_9_6_1","first-page":"109","article-title":"Mycoses invasives en France m\u00e9tropolitaine, PMSI 2001\u20132010: incidence, l\u00e9talit\u00e9 et tendances","volume":"12","author":"Bitar D","year":"2013","journal-title":"Bull Epidemiol Hebd"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3408-3"},{"key":"e_1_2_9_8_1","first-page":"117","article-title":"Usage, impact \u00e9cologique et \u00e9conomique des antifongiques syst\u00e9miques en milieu hospitalier en France","volume":"12","author":"Grenouillet F","year":"2013","journal-title":"Bull Epidemiol Hebd"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.761134"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-014-0415-z"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3640-3645.2005"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annfar.2008.10.004"},{"key":"e_1_2_9_13_1","first-page":"1","article-title":"Prise en charge des candidoses et aspergilloses invasives de l'adulte","volume":"1","author":"Soci\u00e9t\u00e9 fran\u00e7aise d'anesth\u00e9sie et de r\u00e9animation, Soci\u00e9t\u00e9 de pathologie infectieuse de langue fran\u00e7aise, and Soci\u00e9t\u00e9 de r\u00e9animation de langue fran\u00e7aise. Conf\u00e9rence de Consensus commune","year":"2004","journal-title":"Ann Fr Anesth Reanim"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12039"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/513663"},{"key":"e_1_2_9_17_1","first-page":"125","article-title":"Candid\u00e9mies en \u00cele\u2010de\u2010France: donn\u00e9es de l'Observatoire des levures","volume":"12","author":"Renaudat C","year":"2013","journal-title":"Bull Epidemiol Hebd"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/422312"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02427.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066906"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2008.01645.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783X-16-4-159"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585270-000000000-00000"},{"key":"e_1_2_9_24_1","first-page":"528","article-title":"Echinocandins\u2013new antifungal agents","volume":"118","author":"Stan CD","year":"2014","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.324-326.2006"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.02.020"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01701-10"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02165.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02290-12"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60605-9"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02113.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02112.x"},{"key":"e_1_2_9_36_1","first-page":"27","article-title":"Micafungin: an evidence\u2010based review of its place in therapy","volume":"9","author":"Torre P","year":"2014","journal-title":"Core Evid"},{"key":"e_1_2_9_37_1","unstructured":"Astellas Pharma Europe B.V. Mycamine: Summary of Product Characteristics. 2019.https:\/\/www.medicines.org.uk\/emc\/medicine\/20997\/SPC\/Mycamine+50mg+and+100mg+powder+for+solution+for+infusion\/. Accessed November 27 2019."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14786440009463897"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02295996"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31819efac0"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw352"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12038"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-4053-1"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-015-0103-7"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.13060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:07:29Z","timestamp":1694012849000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.13060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/myc.13060"],"URL":"https:\/\/doi.org\/10.1111\/myc.13060","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"2020-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}